Attached files
| file | filename |
|---|---|
| EX-10.1 - EX-10.1 - Bohai Pharmaceuticals Group, Inc. | v208898_ex10-1.htm |
| EX-99.1 - EX-99.1 - Bohai Pharmaceuticals Group, Inc. | v208898_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or Section 15(d) of the Securities Exchange Act of
1934
Date of
Report (Date of Earliest Event Reported): January 21,
2011
Bohai
Pharmaceuticals Group, Inc.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
000-53401
|
98-0588402
|
||
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
|
c/o
Yantai Bohai Pharmaceuticals Group Co. Ltd.
No.
9 Daxin Road, Zhifu District
Yantai,
Shandong Province, China 264000
|
|
(Address
of principal executive offices)
|
Registrant’s
telephone number, including area code: +86(535)-685-7928
n/a
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation to the registrant under any of the following
provisions:
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
|
Item
8.01 Other Events.
On
January 21, 2011, Bohai Pharmaceuticals Group, Inc. (the “Company”) closed a
financing transaction under which it sold an aggregate of 748,382 shares (the
“Shares”) of the Company’s common stock, par value $0.001 per share (the “Common
Stock”), to a total of 42 individual investors (the “Investors”) at $2.50 per
share, for total gross proceeds of $1,870,955. The Shares were sold
pursuant to separate subscription agreements (the form of which is attached
hereto as Exhibit 10.1) between the Company and each Investor, dated as of
January 21, 2011, the date on which the Investors’ subscriptions were accepted
by the Company.
All of
the Investors are domiciled in and citizens of the People’s Republic of
China. The issuance of the Shares was made in reliance on the
exemption from registration provided by Regulation S of the Securities Act of
1933, as amended, as an offshore transaction involving non-U.S.
persons. A press release with respect to the Offering is attached
hereto as Exhibit 99.1.
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits.
10.1 Form
of Subscription Agreement for the Company’s Regulation S financing
99.1 Press
Release, dated January 24, 2011, relating to the Company’s Regulation S
financing
1
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
January
24, 2011
|
BOHAI
PHARMACEUTICALS GROUP, INC.
|
||
|
By:
|
/s/ Gene Hsiao | ||
|
Name: Gene
Hsiao
|
|||
|
Title:
Chief Financial Officer
|
|||